By considering age, TNM stage, and molecular subtype of new BC cases, we have identified potential areas for improvement, such as extending the screening age to older cohorts and adjusting the screening frequency based on the risk for HR−/HER2− or HER2+ tumours. The gene discussed is ERBB2; the disease is neoplasm.